BioPorto A/S (CPH:BIOPOR) (FRA:2P4) announced that it has begun a search for a new CFO after Ole Larsen resigned to pursue opportunities outside the company.
Larsen had served as CFO and a member of the company’s management team since 2018. He will officially leave the company by the end of May and remain available for the company until the end of October.
“It is with regret that we received Ole’s resignation,” CEO Peter Mørch Eriksen said in a statement. “He has been a truly important asset for BioPorto. During his three-year tenure, he has established a strong performing finance organization while focusing on broadening our investor reach and dialogue, which has been pivotal in execution of our funding strategy. I am grateful for his strong contribution and wish him all the best in his future endeavors.”
READ: BioPorto says 2021 "will be a pivotal year" as it publishes its 2020 Annual Report
The search for a successor will be initiated immediately, and BioPorto said it will make an announcement as soon as it has concluded on the search process.
This announcement does not alter BioPorto’s financial guidance for 2021, as presented in its 2020 annual report, the company added.
BioPorto is an in-vitro diagnostic company based in Hellerup, Denmark, that provides healthcare professionals in 80 countries a range of diagnostic tests and antibodies to treat obesity and diabetes, innate immunity, allergies and infectious diseases.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel